Neovasc (TSE:NVC) Rating Lowered to Neutral at HC Wainwright

Neovasc (TSE:NVC – Get Rating) (NASDAQ:NVCN) was downgraded by investment analysts at HC Wainwright from a “buy” rating to a “neutral” rating in a research note issued on Wednesday, PriceTargets.com reports.

Neovasc Stock Performance

Neovasc has a 1-year low of C$0.49 and a 1-year high of C$6.07. The firm’s 50-day moving average is C$1.78.

Neovasc (TSE:NVC – Get Rating) (NASDAQ:NVCN) last posted its earnings results on Thursday, November 10th. The company reported C($3.91) earnings per share for the quarter, missing analysts’ consensus estimates of C($3.67) by C($0.24). The business had revenue of C$1.21 million for the quarter, compared to analysts’ expectations of C$1.37 million.

Insiders Place Their Bets

In other Neovasc news, Director Paul Geyer bought 3,000 shares of Neovasc stock in a transaction on Friday, November 18th. The shares were purchased at an average cost of C$8.71 per share, with a total value of C$26,130.00. Following the acquisition, the director now directly owns 18,335 shares of the company’s stock, valued at approximately C$159,697.85.

Neovasc Company Profile

(Get Rating)

Neovasc Inc (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company’s segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products.